Home/Pipeline/PF-07081532 (GLP-1R)

PF-07081532 (GLP-1R)

Obesity, Type 2 Diabetes

Phase 3Active

Key Facts

Indication

Obesity, Type 2 Diabetes

Phase

Phase 3

Status

Active

Company

Pfizer

About Pfizer

Pfizer's mission is to deliver 'Breakthroughs that change patients' lives' through scientific innovation across a diversified portfolio of therapeutics and vaccines. Its strategic achievements include the rapid development and global commercialization of the COVID-19 vaccine Comirnaty, establishing a leading mRNA platform, and a disciplined pipeline expansion into high-growth areas like obesity and oncology. The company's strategy focuses on sharpening its R&D focus on transformative science, optimizing its cost structure, and deploying capital for strategic business development to drive long-term growth post-pandemic.

View full company profile

Therapeutic Areas

Internal Medicine Oncology Vaccines Inflammation & Immunology Rare Disease

Other Obesity, Type 2 Diabetes Drugs

Drug	Company	Phase	Status
ThermoStem	BioRestorative Therapies	Preclinical	Research & Development
Danuglipron (GLP-1/GIP)	Pfizer	Phase 3	Active
CagriSema (Subcutaneous)	Novo Nordisk	Phase 3	Active
Oral CagriSema	Novo Nordisk	Phase 2	Active